Seelos’ SLS-005 Cleared as 5th Arm of HEALEY ALS Trial

Seelos’ SLS-005 Cleared as 5th Arm of HEALEY ALS Trial

307342

Seelos’ SLS-005 Cleared as 5th Arm of HEALEY ALS Trial

Seelos Therapeutics’ experimental therapy SLS-005 (trehalose) will serve as the fifth arm of the multi-regimen HEALEY trial for amyotrophic lateral sclerosis (ALS), after being cleared by the U.S. Food and Drug Administration and the Mass General Brigham Institutional Review Board. With this final regulatory authorization, Seelos may still meet its plans of starting patient dosing by the end of this month. SLS-005 will be evaluated in a pivotal Phase 2b/3 trial integrated into the HEALEY ALS…

You must be logged in to read/download the full post.